FGEN
Price
$10.38
Change
-$0.39 (-3.62%)
Updated
Oct 17 closing price
Capitalization
41.98M
JAGX
Price
$2.08
Change
-$0.04 (-1.89%)
Updated
Oct 17 closing price
Capitalization
7.71M
Interact to see
Advertisement

FGEN vs JAGX

Header iconFGEN vs JAGX Comparison
Open Charts FGEN vs JAGXBanner chart's image
FibroGen
Price$10.38
Change-$0.39 (-3.62%)
Volume$10.11K
Capitalization41.98M
Jaguar Health
Price$2.08
Change-$0.04 (-1.89%)
Volume$83.1K
Capitalization7.71M
FGEN vs JAGX Comparison Chart in %
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. JAGX commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a Hold and JAGX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (FGEN: $10.38 vs. JAGX: $2.08)
Brand notoriety: FGEN and JAGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 25% vs. JAGX: 48%
Market capitalization -- FGEN: $41.98M vs. JAGX: $7.71M
FGEN [@Biotechnology] is valued at $41.98M. JAGX’s [@Biotechnology] market capitalization is $7.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileJAGX’s FA Score has 1 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • JAGX’s FA Score: 1 green, 4 red.
According to our system of comparison, FGEN is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 5 TA indicator(s) are bullish while JAGX’s TA Score has 4 bullish TA indicator(s).

  • FGEN’s TA Score: 5 bullish, 4 bearish.
  • JAGX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, FGEN is a better buy in the short-term than JAGX.

Price Growth

FGEN (@Biotechnology) experienced а -1.61% price change this week, while JAGX (@Biotechnology) price change was +0.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FGEN($42M) has a higher market cap than JAGX($7.71M). FGEN YTD gains are higher at: -21.586 vs. JAGX (-91.762). JAGX has higher annual earnings (EBITDA): -38.75M vs. FGEN (-77.3M). FGEN has more cash in the bank: 23.4M vs. JAGX (2.21M). JAGX has less debt than FGEN: JAGX (30.5M) vs FGEN (73.7M). JAGX has higher revenues than FGEN: JAGX (11.8M) vs FGEN (7.35M).
FGENJAGXFGEN / JAGX
Capitalization42M7.71M545%
EBITDA-77.3M-38.75M200%
Gain YTD-21.586-91.76224%
P/E RatioN/A0.06-
Revenue7.35M11.8M62%
Total Cash23.4M2.21M1,060%
Total Debt73.7M30.5M242%
FUNDAMENTALS RATINGS
FGEN vs JAGX: Fundamental Ratings
FGEN
JAGX
OUTLOOK RATING
1..100
5638
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4365
P/E GROWTH RATING
1..100
46100
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (16) in the Pharmaceuticals Generic industry is significantly better than the same rating for FGEN (93) in the Biotechnology industry. This means that JAGX’s stock grew significantly faster than FGEN’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as FGEN (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to FGEN’s over the last 12 months.

JAGX's SMR Rating (100) in the Pharmaceuticals Generic industry is in the same range as FGEN (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to FGEN’s over the last 12 months.

FGEN's Price Growth Rating (43) in the Biotechnology industry is in the same range as JAGX (65) in the Pharmaceuticals Generic industry. This means that FGEN’s stock grew similarly to JAGX’s over the last 12 months.

FGEN's P/E Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that FGEN’s stock grew somewhat faster than JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENJAGX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 3 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CPRX20.550.02
+0.10%
Catalyst Pharmaceuticals
CODI7.30-0.18
-2.41%
Compass Diversified
ATRA14.81-0.43
-2.85%
Atara Biotherapeutics Inc.
SCKT0.93-0.04
-4.13%
Socket Mobile
SMMT20.99-0.98
-4.46%
Summit Therapeutics

FGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, FGEN has been loosely correlated with AVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FGEN jumps, then AVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FGEN
1D Price
Change %
FGEN100%
-3.67%
AVTX - FGEN
57%
Loosely correlated
+9.64%
AXON - FGEN
43%
Loosely correlated
+2.84%
INSM - FGEN
39%
Loosely correlated
+1.57%
AMRN - FGEN
35%
Loosely correlated
-2.14%
JAGX - FGEN
34%
Loosely correlated
-1.89%
More

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with FGEN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then FGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-1.89%
FGEN - JAGX
34%
Loosely correlated
-3.67%
RXRX - JAGX
32%
Poorly correlated
-7.86%
MRNA - JAGX
31%
Poorly correlated
-4.16%
RNAZ - JAGX
31%
Poorly correlated
+2.08%
XENE - JAGX
30%
Poorly correlated
-1.28%
More